Free Trial

Trevi Therapeutics (TRVI) News Today

Trevi Therapeutics logo
$2.94
-0.12 (-3.92%)
(As of 10/31/2024 ET)
Trevi Therapeutics, Inc. stock logo
Trevi Therapeutics (TRVI) Set to Announce Quarterly Earnings on Wednesday
Trevi Therapeutics (NASDAQ:TRVI) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.
Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at HC Wainwright
Trevi Therapeutics, Inc. stock logo
Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Trevi Therapeutics in a research note on Tuesday.
Trevi Therapeutics completes enrollment for Phase 2a RIVER trial
Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) PT at $7.43
Trevi Therapeutics, Inc. stock logo
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned an average recommendation of "Buy" from the nine analysts that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to
Trevi Therapeutics, Inc. stock logo
Leerink Partnrs Has Negative Outlook of TRVI FY2024 Earnings
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of Trevi Therapeutics in a research note issued on Tuesday, October 15th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will e
Trevi Therapeutics, Inc. stock logo
Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday.
Trevi Therapeutics, Inc. stock logo
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Lifted by Logos Global Management LP
Logos Global Management LP grew its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 27.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,800,000 shares of the company's stock af
Trevi Therapeutics, Inc. stock logo
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned an average rating of "Buy" from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have assigned a st
Trevi Therapeutics, Inc. stock logo
1,474,926 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Ally Bridge Group NY LLC
Ally Bridge Group NY LLC purchased a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,474,926 shares of the company's stock, valued at ap
Trevi Therapeutics, Inc. stock logo
Rubric Capital Management LP Sells 537,192 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)
Rubric Capital Management LP trimmed its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 9.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,026,931 shares of the company's stock a
Trevi Therapeutics, Inc. stock logo
Leerink Partnrs Comments on Trevi Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:TRVI)
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities research analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for Trevi Therapeutics in a research report issued on Monday, September 9th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnin
Trevi Therapeutics, Inc. stock logo
Q1 2025 Earnings Estimate for Trevi Therapeutics, Inc. (NASDAQ:TRVI) Issued By Leerink Partnrs
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Trevi Therapeutics in a research note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid anticipates that
Trevi Therapeutics, Inc. stock logo
Trevi Therapeutics (NASDAQ:TRVI) Raised to "Strong-Buy" at Leerink Partnrs
Leerink Partnrs upgraded shares of Trevi Therapeutics to a "strong-buy" rating in a research note on Monday.
Trevi Therapeutics, Inc. stock logo
Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 4,219 Shares of Stock
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 4,219 shares of the firm's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $3.03, for a total transaction of $12,783.57. Following the completion of the sale, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $646,338.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Trevi Therapeutics, Inc. stock logo
Trevi Therapeutics (NASDAQ:TRVI) Research Coverage Started at Leerink Partners
Leerink Partners initiated coverage on Trevi Therapeutics in a report on Monday. They issued an "outperform" rating and a $7.00 price objective on the stock.
Get Trevi Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.

$5k to $1.3m in just 3 trades (Ad)

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

Register for the imminent briefing here.

TRVI Media Mentions By Week

TRVI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TRVI
News Sentiment

0.63

0.68

Average
Medical
News Sentiment

TRVI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TRVI Articles
This Week

4

3

TRVI Articles
Average Week

Get Trevi Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:TRVI) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners